127 related articles for article (PubMed ID: 8805030)
1. Treatment of prediabetic patients with insulin: experience and future. European Prediabetes Study Group.
Carel JC; Bougnères PF
Horm Res; 1996; 45 Suppl 1():44-7. PubMed ID: 8805030
[TBL] [Abstract][Full Text] [Related]
2. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
Roman G; Hancu N
Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
[TBL] [Abstract][Full Text] [Related]
3. Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial.
Heiskanen MA; Motiani KK; Mari A; Saunavaara V; Eskelinen JJ; Virtanen KA; Koivumäki M; Löyttyniemi E; Nuutila P; Kalliokoski KK; Hannukainen JC
Diabetologia; 2018 Aug; 61(8):1817-1828. PubMed ID: 29717337
[TBL] [Abstract][Full Text] [Related]
4. What are the pharmacotherapy options for treating prediabetes?
Daniele G; Abdul-Ghani M; DeFronzo RA
Expert Opin Pharmacother; 2014 Oct; 15(14):2003-18. PubMed ID: 25139488
[TBL] [Abstract][Full Text] [Related]
5. Metformin Use in Children and Adolescents with Prediabetes.
Khokhar A; Umpaichitra V; Chin VL; Perez-Colon S
Pediatr Clin North Am; 2017 Dec; 64(6):1341-1353. PubMed ID: 29173789
[TBL] [Abstract][Full Text] [Related]
6. Preservation of β-cell function: the key to diabetes prevention.
DeFronzo RA; Abdul-Ghani MA
J Clin Endocrinol Metab; 2011 Aug; 96(8):2354-66. PubMed ID: 21697254
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
Trials; 2015 Nov; 16():496. PubMed ID: 26530718
[TBL] [Abstract][Full Text] [Related]
8. Insulin and the prevention of insulin-dependent diabetes mellitus.
Coutant R; Carel JC; Timsit J; Boitard C; Bougnères P
Diabetes Metab; 1997 Sep; 23 Suppl 3():25-8. PubMed ID: 9342539
[TBL] [Abstract][Full Text] [Related]
9. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging pharmacotherapy for prediabetes: are we moving forward?
Mangan A; Docherty NG; Le Roux CW; Al-Najim W
Expert Opin Pharmacother; 2018 Oct; 19(15):1663-1673. PubMed ID: 30198813
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
Smith-Marsh D
Drugs Today (Barc); 2013 Aug; 49(8):499-507. PubMed ID: 23977667
[TBL] [Abstract][Full Text] [Related]
12. [Perspectives of the use of antihyperglycemic preparations in patients with metabolic syndrome and prediabetes].
Mamedov MN; Shishkova VN
Kardiologiia; 2007; 47(6):88-93. PubMed ID: 18260885
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide prevents diabetes progression in prediabetic OLETF rats.
Guo N; Sun J; Chen H; Zhang H; Zhang Z; Cai D
Endocr J; 2013; 60(1):15-28. PubMed ID: 22986487
[TBL] [Abstract][Full Text] [Related]
14. Novel Strategies for Inducing Glycemic Remission during the Honeymoon Phase of Type 2 Diabetes.
Retnakaran R
Can J Diabetes; 2015 Dec; 39 Suppl 5():S142-7. PubMed ID: 26653254
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy.
Rolon MA; Benali K; Munck A; Navarro J; Clement A; Tubiana-Rufi N; Czernichow P; Polak M
Acta Paediatr; 2001 Aug; 90(8):860-7. PubMed ID: 11529531
[TBL] [Abstract][Full Text] [Related]
17. The role of incretin-based therapies in prediabetes: a review.
Ahmadieh H; Azar ST
Prim Care Diabetes; 2014 Dec; 8(4):286-94. PubMed ID: 24666932
[TBL] [Abstract][Full Text] [Related]
18. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
[TBL] [Abstract][Full Text] [Related]
19. Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?
Vaag A; Lund SS
Appl Physiol Nutr Metab; 2007 Oct; 32(5):912-20. PubMed ID: 18059616
[TBL] [Abstract][Full Text] [Related]
20. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
